GeneMind core pan-cancer panel is a targeted sequencing assay for biomarker analysis of over 130 genes with known relevance to solid tumors based on hybrid capture technology, covering all major variant classes plus microsatellite instability (MSI) and mismatch repair (MMR) related genes, which provide reference for targeted therapy, chemotherapy, immunotherapy and hereditary tumor risk assessment. Test results provide a comprehensive medication guidance for patients.
Capable of detecting low - frequency variants as low as 0.2% in ctDNA; supports both tissue and liquid biopsy samples
Capable of detecting multiple types of variants such as SNVs, InDels, CNVs, SVs, etc
100+ unlinked SNP loci. Capable of detecting cross - individual human contamination at a minimum level of 1%
Combined with the backbone strategy, it can detect CNVs as low as 3.0 copies
|
Product |
Lung & Colon Cancer 130 Panel |
||||
|
Methods |
Hybrid capture |
||||
|
Gene number |
130+ |
||||
|
Panel size |
~700 kb |
||||
|
Variants type |
SNVs, InDels, CNVs, SVs |
||||
|
Input quantity |
20 ng ~ 500 ng DNA |
||||
|
Sample types |
FFPE, fresh tissue, plasma, white blood cells, pleural fluid and ascitic fluid |
||||
|
Mapping rate |
98.99% |
||||
|
On-target rate |
>70% |
||||
|
Coverage uniformity |
96% |
||||
|
Sequencing platform（PE150） |
FASTASeq 300 |
GenoLab M |
SURFSeq 5000 |
FASTASeq S |
|
|
No.of sample/FC |
Tissue/White blood cell (≥2 Gb) |
1 FCM: 12 1 FCH: 28 1 FCP：56 |
1 FCM: 28 1 FCH: 56 |
1 FCM: 56 1 FCP: 432 |
1 FCL: 2 1 FCM: 4 |
|
Plasma (≥14 Gb) |
1 FCM: 2 1 FCH: 4 1 FCP: 8 |
1 FCM: 4 1 FCH: 8 |
1 FCM: 8 1 FCH: 36 1 FCP: 72 |
- |
|
|
Turn-around-time |
3-5 days |
||||
|
Report generation |
Local analysis and report system |
||||
